Production Milestone: IperionX announced its March quarterly report, highlighting a transition to 24/7 continuous titanium production at its Virginia facility. Social media discussions emphasize this shift as a pivotal step toward a domestic supply chain for U.S. defense needs. Backed by substantial government funding, the move has sparked widespread investor interest.
Share Price Momentum: Shares rose approximately 4% recently, extending a 32% gain over the past month. Enthusiasts on social media point to ramped-up output and U.S. Department of Defense support exceeding $47 million as catalysts. The focus remains on scaling operations amid critical minerals independence efforts.
Strategic Expansion: Conversations underscore progress on the Titan Critical Minerals Project alongside titanium metal scaling. Social media users view the continuous operations as enhancing America's manufacturing resilience. The quarterly update continues to fuel optimistic outlooks on future growth.
Note: This discussion summary was generated from an AI condensation of post data.
IperionX Insider Trading Activity
IperionX insiders have traded $IPX stock on the open market 8 times in the past 6 months. Of those trades, 8 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IPX stock by insiders over the last 6 months:
- TODD HANNIGAN (Executive Chairman) has made 3 purchases buying 705,225 shares for an estimated $2,798,706 and 0 sales.
- ANASTASIOS ARIMA (Chief Executive Officer) has made 3 purchases buying 589,800 shares for an estimated $2,286,735 and 0 sales.
- TOBY EDGCUMBE SYMONDS (President) purchased 11,000 shares for an estimated $262,552
- R TONY TRIPENY purchased 4,187 shares for an estimated $99,463
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
IperionX Hedge Fund Activity
We have seen 33 institutional investors add shares of IperionX stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VAN ECK ASSOCIATES CORP added 506,612 shares (+61.0%) to their portfolio in Q4 2025, for an estimated $18,331,755
- SHAY CAPITAL LLC removed 154,303 shares (-53.3%) from their portfolio in Q4 2025, for an estimated $5,583,454
- MILLENNIUM MANAGEMENT LLC added 117,436 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,249,421
- MORGAN STANLEY added 75,034 shares (+135.3%) to their portfolio in Q4 2025, for an estimated $2,715,105
- WOODLINE PARTNERS LP added 68,846 shares (+68.7%) to their portfolio in Q4 2025, for an estimated $2,491,192
- STIFEL FINANCIAL CORP removed 68,369 shares (-7.6%) from their portfolio in Q4 2025, for an estimated $2,473,932
- JANE STREET GROUP, LLC added 49,645 shares (+62.5%) to their portfolio in Q4 2025, for an estimated $1,796,404
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
IperionX Analyst Ratings
Wall Street analysts have issued reports on $IPX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 03/27/2026
- Roth Capital issued a "Buy" rating on 01/20/2026
- William Blair issued a "Outperform" rating on 01/13/2026
To track analyst ratings and price targets for IperionX, check out Quiver Quantitative's $IPX forecast page.
IperionX Price Targets
Multiple analysts have issued price targets for $IPX recently. We have seen 3 analysts offer price targets for $IPX in the last 6 months, with a median target of $52.0.
Here are some recent targets:
- Gregory Lewis from BTIG set a target price of $40.0 on 03/27/2026
- Lucas Pipes from B. Riley Securities set a target price of $52.0 on 03/13/2026
- Joe Reagor from Roth Capital set a target price of $74.0 on 01/20/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
